TGTX Q4 2022 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80,000-96.6% YoY

Gross Profit

$77,00096.3% margin

Operating Income

-$52M-65077.5% margin

Net Income

-$53M-66242.5% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-14.9%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$194M

Total Liabilities

$135M

Stockholders' Equity

$59M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80,000	$2M	-96.6%
Gross Profit	$77,000	$2M	-96.4%
Operating Income	-$52M	-$93M	+44.0%
Net Income	-$53M	-$93M	+43.2%

Revenue Segments

Product revenue, net

$42,00053%

License revenue

$38,00048%